Drug Profile
Basmisanil - Roche
Alternative Names: GABRA5 negative allosteric modulator (NAM) - Roche; RG-1662; RO-5186582Latest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Roche
- Developer Chugai Pharmaceutical; Roche
- Class Antidementias; Oxazoles; Pyridines; Small molecules; Thiamorpholines
- Mechanism of Action GABA A alpha 5 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Down syndrome; Neurological disorders; Pervasive child development disorders; Schizophrenia
Most Recent Events
- 15 Feb 2024 Discontinued - Phase-II for Pervasive child development disorders (In children) in Australia, United Kingdom, Spain, Italy (PO) (Roche pipeline, February 2024)
- 21 Jun 2023 Roche plans to submit regulatory fillings in Pervasive child development disorders, in or after 2026 (Roche pipeline, June 2023)
- 16 Dec 2022 Phase-II clinical trials in Pervasive child development disorders (In children) in Italy, Spain, United Kingdom, Australia (PO) (NCT05307679)